Home » Topics » BioWorld Science

BioWorld Science
RSS

Quilimmune-P enters phase II

Jan. 23, 1998

Antegren meets development criteria in phase II trial

Jan. 23, 1998

Boston Life Sciences to seek U.S. approval for Therafectin

Jan. 23, 1998

Alkermes, Johnson & Johnson to codevelop novel formulation of erythropoietin

Jan. 23, 1998

T Cell Sciences awarded SBIR grant for atherosclerosis vaccine

Jan. 23, 1998

Viracept approved for marketing in E.U. member countries

Jan. 23, 1998

HMR's new ketolides extensively discussed at conference this week

Jan. 23, 1998

Clinical results reported for Servier's MDR-reversing agent S-9788

Jan. 23, 1998

Abbott presents in vitro and in vivo efficacy data on tricyclic ketolides

Jan. 23, 1998

Lexacalcitol: a vitamin D analogue with increased potency

Jan. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...